Stem cell therapy uses stem cells or cells derived from them, with evidence that depends on the exact product and condition. Some uses are established, while many interventions promoted for joint problems, neurological conditions or wellness remain under investigation. For patients considering PRMEDICA in San José del Cabo, Los Cabos, this guide explains treatment terms, research limits and the medical assessment needed before a decision. [1]
If you are considering care at PRMEDICA in Los Cabos, start with a medical assessment and a discussion of alternatives. This guide explains terminology, research findings and the questions to address before making a treatment decision.
Discuss your condition, existing studies and goals before deciding whether a treatment or trip is appropriate. Discuss Your Medical History with PRMEDICA
At a glance
| Topic | What to know |
|---|---|
| Purpose | Understand the options, evidence and questions that inform a medical assessment. |
| Products | MSCs, Muse cells and exosome preparations are not interchangeable. |
| Eligibility | A diagnosis and individualized assessment are needed; an inquiry does not establish suitability. |
| Visits and recovery | Depend on the proposed procedure and your health; no universal schedule applies. |
| Results | Require defined goals and follow-up. Benefits are not guaranteed. |
| Costs | Request an itemized quotation after discussing the proposed care. |
Understanding the terms
The phrase “stem cell therapy” does not identify one standardized treatment. Products can differ in cell source, preparation and intended use. Cells obtained from the same patient are called autologous; cells obtained from another person are called allogeneic. Ask which description applies to the product being discussed. [1]
| Term | What it describes | What to clarify |
|---|---|---|
| MSCs | Mesenchymal stromal cells, often marketed as mesenchymal stem cells. The ISCT recommends specifying their tissue source and supporting claimed properties. [2] | Which product and tissue source are proposed, and what evidence supports this use? |
| Muse cells | Multilineage-differentiating stress-enduring cells, a population studied within the broader field of cell therapy. Research includes a specific Muse cell product called CL2020. [3] | How is the product identified, and does the cited research actually study that preparation? |
| Exosomes | A type of extracellular vesicle released by cells. Vesicles are particles rather than living stem cells; their characterization matters. [4] | What does the preparation contain, how is it characterized and what human evidence supports its proposed use? |
None of these names, by itself, establishes that a product is appropriate for your condition. A comparison should identify the preparation and clinical evidence, not rank the options as basic, advanced or universally superior.
What the evidence can and cannot tell you
Research should be interpreted at the level of the product, patient population and treatment method studied. A finding for one condition or preparation cannot automatically be applied to another. Laboratory findings and patient testimonials also answer different questions from controlled human studies.
Established uses and product-specific approvals
Blood-forming stem cell transplantation has established uses for selected blood and immune disorders. These treatments are different from many interventions marketed under the broad label of regenerative medicine. [1]
An approval applies to a defined product and use. For example, the FDA lists RYONCIL for a specific complication of transplantation, steroid-refractory acute graft-versus-host disease, in children aged two months and older. This does not establish approval for another MSC product or for joint pain, and does not mean PRMEDICA offers RYONCIL. [5]
Joint symptoms and knee osteoarthritis
A 2025 Cochrane review of 25 randomized trials involving 1,341 participants found that stem cell injections may slightly improve knee pain and function compared with placebo, with low-certainty evidence. Effects on disease progression and safety remain uncertain. This does not establish cartilage regrowth or the benefit of a different product or intravenous treatment. [6]
Muse cell research
A small randomized trial studied CL2020, a specific Muse cell product, in 35 people after ischemic stroke. It reported a possible functional benefit, but adverse reactions included a severe seizure-related event. These findings are preliminary and cannot establish the effects of another preparation marketed as Muse cells or its use for wellness. [3]
Exosomes and wellness claims
Extracellular vesicle research requires careful characterization of the material being studied. A label such as “exosomes” does not establish the identity, purity or clinical effect of a commercial preparation. [4]
Before accepting claims about rejuvenation, longevity or improvement across multiple diseases, ask for human evidence for the exact product and proposed use. The fact that a clinic offers an intervention is not proof that its benefits have been established. [1]
How medical eligibility is assessed
An assessment begins with a clear understanding of the problem you want treated. Tell the physician about your diagnosis, how symptoms affect daily life, treatments already tried and the outcome you hope to achieve. If the diagnosis is uncertain, further evaluation may be more useful than choosing a procedure.
Bring a current list of medicines and supplements, allergies, significant illnesses and relevant reports or imaging. Tell the team about prior reactions to treatment and any recent change in your health. The physician should explain which details affect the decision and whether additional tests are needed.
Eligibility is specific to the intervention. The discussion may lead to further investigation, referral, consideration of established care or a recommendation not to proceed. Do not change prescribed treatment on your own while exploring options.
An assessment can help clarify the diagnosis, available options and whether further information is needed. Contact PRMEDICA to ask how to begin. Ask About a Medical Assessment
What a personalized plan should explain
A proposed plan should connect the treatment to a defined clinical question. Ask what improvement would matter in your case, how it would be measured and when the result would be reviewed. The discussion should include alternatives and the possibility that the intervention may not help. [7]
| Part of the plan | Information to request |
|---|---|
| Clinical goal | The symptom or functional limitation being addressed and a baseline for comparison. |
| Intervention | Named product, source, proposed administration and medical rationale. |
| Schedule | Appointments, observation and follow-up appropriate to the proposed procedure. |
| Consent | Expected benefits, uncertainty, risks and alternatives in understandable language. |
| Review | How results and adverse effects will be assessed, and who coordinates later care. |
Additional treatments should each have a stated purpose. Combining several interventions can make it harder to know which one caused an improvement or adverse effect. Ask why each component is proposed before agreeing to a package.
Safety and treatment oversight
Risk depends on the product, its preparation, administration and the patient’s condition. Reports involving unapproved regenerative products have included serious infections, immune or inflammatory reactions and other harmful outcomes. Such reports do not estimate the risk of a particular PRMEDICA protocol; that requires product-specific information and medical review. [8]
Ask the physician to distinguish risks of the procedure from uncertainties about the biological product. Request instructions for unexpected symptoms and clarify how urgent medical care would be accessed. Discuss longer-term uncertainties as well as the immediate experience.
For care in Mexico, ask for the applicable documentation for the establishment, product and proposed use, including research oversight where relevant. A foreign approval or trial registration alone should not be treated as authorization for a different product or procedure in Mexico.
Preparing for a visit to Los Cabos
Before booking travel, discuss the proposed care with the clinician who normally manages your condition. Clarify the expected appointments, whether an accompanying person is needed and who will manage care when you return. Your itinerary should accommodate medical advice rather than determine the treatment schedule. [9]
Request treatment records and clear follow-up instructions. Confirm a contact for non-urgent questions, a plan for urgent care and any restrictions on travel or activities. Do not assume that a visit can be combined with every planned vacation activity. [9]
Understanding the budget
Once the proposed care is clear, request a quotation that separates treatment, tests, follow-up and other charges. Confirm travel expenses and payment terms before making commitments.
For a practical checklist of what to include and compare, read Stem Cell Therapy Cost in Mexico
Starting a conversation with PRMEDICA
Meet the PRMEDICA medical team.
PRMEDICA is located in San José del Cabo, in the Los Cabos region of Baja California Sur, Mexico. Ask the team which assessment options are available for local and international patients.
For the clinic’s service information, see cellular therapy at PRMEDICA
Contact PRMEDICA in San José del Cabo with your questions about assessment. Ask which records the medical team needs and how to share them through the designated channel. A discussion should help you understand the next step without committing you to a procedure.
Bring your diagnosis, goals and questions to a medical discussion before deciding on treatment. Discuss Your Medical History with PRMEDICA
Frequently asked questions
Are Muse cells a better option than MSCs?
There is no universal ranking that answers this for every patient. Ask which specific preparation is proposed, what comparative evidence exists for your condition and whether that evidence applies to the planned administration.
Can a study of stem cells support an exosome treatment?
Not by itself. Exosomes are extracellular vesicles, not living stem cells. Ask for evidence about the actual preparation and proposed use; findings from a cellular treatment cannot establish the same effect for an exosome preparation. [4]
Does a published study mean a treatment is approved?
No. A publication reports research findings; authorization concerns a particular product and use under a specific regulatory system. Ask what documentation applies to the exact intervention being offered.
Can I be assessed if I do not have a diagnosis?
You can ask about a medical evaluation, but the first priority may be establishing the cause of your symptoms. A treatment package should not substitute for that work.
How many sessions would I need?
There is no schedule that applies to all cellular interventions. Ask the physician to explain the proposed number of applications, the evidence supporting that schedule and how the need for further care would be reviewed.
How soon could I know whether treatment helped?
The appropriate review period depends on the condition and intervention. Agree on meaningful measures and follow-up timing before treatment. Early changes in symptoms do not, by themselves, demonstrate tissue regeneration.
What if the medical team does not recommend treatment?
Ask for an explanation of the findings and appropriate next steps, which may involve further investigation or other care. A recommendation not to proceed can be an important outcome of the assessment.
This guide is educational and does not replace individual medical advice. The research examples do not establish the suitability, authorization or availability of a particular treatment at PRMEDICA.
Sources and references
- ISSCR — 9 Things to Know About Stem Cell Treatments
- Viswanathan et al. 2019 — ISCT position statement on MSC nomenclature
- Niizuma et al. 2023 — Randomized placebo-controlled trial of CL2020 in subacute ischemic stroke
- Welsh et al. 2024 — MISEV2023 recommendations on extracellular vesicle research
- FDA — RYONCIL product and indication
- Whittle et al. 2025 — Stem cell injections for osteoarthritis of the knee
- ISSCR — Questions before considering an unproven stem cell treatment
- FDA — Important Patient and Consumer Information About Regenerative Medicine Therapies
- CDC Yellow Book 2026 — Medical Tourism
